Wachtell-Led Immunovant Lands $200M From Top Shareholder
Immunovant said Monday it grabbed a $200 million investment from controlling shareholder Roivant Sciences in a deal guided by Wachtell, as it looks to further develop an experimental drug for people...To view the full article, register now.
Already a subscriber? Click here to view full article